SCHEMBL16303697

SCHEMBL16303697

Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)nn2)c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 20/20 0.70
FLT3 P36888 13/20 0.70
KIT P10721 11/20 0.70
CSF1R P07333 10/20 0.70
FLT4 P35916 10/20 0.70
FLT1 P17948 9/20 0.70
LYN P07948 8/20 0.70
SRC P12931 7/20 0.70
BLK P51451 7/20 0.70
PLK4 O00444 4/20 0.70
AURKA O14965 4/20 0.70
ROCK2 O75116 4/20 0.70
MET P08581 4/20 0.70
PRKACA P17612 4/20 0.70
RPS6KB1 P23443 4/20 0.70
CSNK1D P48730 4/20 0.70
STK3 Q13188 4/20 0.70
ROCK1 Q13464 4/20 0.70
MARK2 Q7KZI7 4/20 0.70
AURKB Q96GD4 4/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16303698 0.86 KDR (0.69) KDRFLT3KITCSF1RFLT4
SCHEMBL16303687 0.86 KDR (0.68) KDRFLT3KITCSF1RFLT4
SCHEMBL16303696 0.86 KDR (0.68) KDRFLT3KITCSF1RFLT4
SCHEMBL422603 0.85 KDR (0.78) KDRFLT3KITCSF1RFLT4
SCHEMBL3469407 0.85 KDR (0.79) KDRFLT3KITCSF1RFLT4
SCHEMBL16303694 0.85 KDR (0.77) KDRFLT3KITCSF1RFLT4
Water SCHEMBL15808658 0.84 KDR (0.78) KDRFLT3KITCSF1RFLT4
Linifanib SCHEMBL29375368 0.82 KDR (1.00) KDRFLT3KITCSF1RFLT4
Linifanib SCHEMBL93804 0.82 KDR (1.00) KDRFLT3KITCSF1RFLT4
SCHEMBL424019 0.82 KDR (0.79) KDRFLT3KITCSF1RFLT4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11352343-B2 Urea derivatives and uses thereof KALA PHARMACEUTICALS, INC. (US) 2022-06-07 US disclosed
US-20200299272-A1 Urea Derivatives and Uses Thereof KALA BIO, Inc. 2020-09-24 US disclosed
US-10723719-B2 Urea derivatives and uses thereof KALA PHARMACEUTICALS, INC. (US) 2020-07-28 US disclosed
US-20190284172-A1 Urea Derivatives and Uses Thereof KALA BIO, Inc. 2019-09-19 US disclosed
US-10329280-B2 Urea derivatives and uses thereof KALA PHARMACEUTICALS, INC. (US) 2019-06-25 US disclosed
US-10316022-B2 Urea derivatives and uses thereof KALA PHARMACEUTICALS, INC. (US) 2019-06-11 US disclosed
US-20180037573-A1 UREA DERIVATIVES AND USES THEREOF KALA BIO, Inc. 2018-02-08 US disclosed
US-20180037572-A1 UREA DERIVATIVES AND USES THEREOF KALA BIO, Inc. 2018-02-08 US disclosed
US-9802922-B2 Urea derivatives and uses thereof KALA PHARMACEUTICALS, INC. (US) 2017-10-31 US disclosed
US-20170129876-A1 UREA DERIVATIVES AND USES THEREOF KALA BIO, Inc. 2017-05-11 US disclosed
US-9580421-B2 Urea derivatives and uses thereof KALA PHARMACEUTICALS, INC. (US) 2017-02-28 US disclosed
US-20160060264-A1 UREA DERIVATIVES AND USES THEREOF KALA BIO, Inc. 2016-03-03 US disclosed
US-9212145-B2 Urea derivatives and uses thereof KALA PHARMACEUTICALS, INC. (US) 2015-12-15 US disclosed
US-20150072986-A1 UREA DERIVATIVES AND USES THEREOF KALA BIO, Inc. 2015-03-12 US disclosed
WO-2014201127-A2 UREA DERIVATIVES AND USES THEREOF KALA PHARMACEUTICALS, INC. (US) 2014-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150072986-A1 UREA DERIVATIVES AND USES THEREOF UACA, RB1, FLT1 KDR 6/4885FLT3 62/4885KIT 51/4885
US-10316022-B2 Urea derivatives and uses thereof UACA, RB1, FLT1 KDR 6/4885FLT3 62/4885KIT 51/4885
US-11352343-B2 Urea derivatives and uses thereof UACA, RB1, FLT1 KDR 6/4885FLT3 62/4885KIT 51/4885
US-20180037572-A1 UREA DERIVATIVES AND USES THEREOF UACA, RB1, FLT1 KDR 6/4885FLT3 62/4885KIT 51/4885
US-10723719-B2 Urea derivatives and uses thereof UACA, RB1, FLT1 KDR 6/4885FLT3 62/4885KIT 51/4885
US-20180037573-A1 UREA DERIVATIVES AND USES THEREOF UACA, RB1, FLT1 KDR 6/4885FLT3 62/4885KIT 51/4885
US-20200299272-A1 Urea Derivatives and Uses Thereof UACA, RB1, FLT1 KDR 6/4885FLT3 62/4885KIT 51/4885
US-10329280-B2 Urea derivatives and uses thereof UACA, RB1, FLT1 KDR 6/4885FLT3 62/4885KIT 51/4885
US-20190284172-A1 Urea Derivatives and Uses Thereof UACA, RB1, FLT1 KDR 6/4885FLT3 62/4885KIT 51/4885
US-20170129876-A1 UREA DERIVATIVES AND USES THEREOF UACA, RB1, FLT1 KDR 6/4885FLT3 62/4885KIT 51/4885
US-20160060264-A1 UREA DERIVATIVES AND USES THEREOF UACA, RB1, FLT1 KDR 6/4885FLT3 62/4885KIT 51/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.